The company that walked into the operating room and asked an awkward question: what if recovery didn't need a bottle of opioids?
The surgeon finishes. The wound is closed. And in the quiet minutes before the patient wakes, a decision gets made that used to be automatic: reach for the opioids. Except in a growing number of those rooms, the reach goes somewhere else entirely - to a syringe of milky-white suspension called EXPAREL, or a handheld wand that numbs a nerve with nothing but cold. The patient will wake up with pain controlled and a medicine cabinet that never met an oxycodone. That quiet swap is the entire reason Pacira BioSciences exists.
Pacira (Nasdaq: PCRX) is a biopharmaceutical company with an unusually stubborn thesis: that the default tool for surgical and chronic pain - the opioid - is overused, and that better engineering can make it optional. It is not a slogan they printed on a mug. It is a product line, a manufacturing platform, a research pipeline, and roughly 790 people organized around one neural pain pathway.
"2025 was a year of disciplined execution. Our products benefitted more than 2.5 million patients and achieved the highest gross margins in our company's history." - Frank D. Lee, CEO
The company began in 2006, in Summit, New Jersey, under the decidedly un-catchy name 21st Century BioPharmaceuticals, built on drug-delivery technology with San Diego roots. It rebranded to Pacira, went public in 2011, and in 2012 launched the product that would define it. Two decades later its headquarters sits in Tampa, Florida, with operations stretching to California - a Brisbane address and San Diego science among them.
What is worth pausing on is the timing. Pacira's founding idea predated the public reckoning with the opioid epidemic by years. When EXPAREL launched in 2012, "opioid-sparing" was a niche phrase, not a national priority. By the time the country was openly counting the cost of overprescription, Pacira already had a commercial product, a manufacturing platform, and a sales force trained to talk to surgeons about an alternative. Being early is usually a curse in pharma. Here it became the moat.
You wrap it in fat. Specifically, in DepoFoam - a proprietary platform that packs a drug into microscopic, honeycomb-like multivesicular liposomes. Picture a cluster of tiny soap bubbles, each holding a dose, each draining on its own schedule. The drug is never chemically altered; it just leaks out slowly, turning a single injection into days of relief. It is less a new molecule than a clever piece of packaging - and packaging, it turns out, is where the magic was hiding.
Honeycomb fat bubbles that hold and slowly release standard anesthetic.
The drug stays the drug. The delivery does the work.
Postsurgical pain control that outlasts the recovery room.
iovera skips chemistry entirely - it freezes the nerve, drug-free.
The elegance of the approach is that it does not ask doctors to gamble on an exotic new compound. EXPAREL is bupivacaine, a local anesthetic clinicians have trusted for decades. Pacira's contribution is the choreography - how the drug arrives, how long it lingers, and how gracefully it leaves. That is a quieter kind of innovation than a novel molecule, and a harder one to copy, because the value lives in the manufacturing rather than in a single patent on a chemical structure.
iovera takes the same instinct to its logical extreme. Why deliver a drug at all, the device asks, when a precisely controlled dose of cold can interrupt a nerve's pain signal on its own? The wand briefly freezes a targeted nerve, the signal goes quiet, and the nerve recovers over time. No prescription, no pill, no metabolite. It is the rare medical product whose active ingredient is temperature.
Bupivacaine liposome injectable suspension. The long-acting local anesthetic built on DepoFoam that turned a 2.5-million-patient idea into a $575M franchise.
The first and only FDA-approved extended-release intra-articular injection for osteoarthritis knee pain. Acquired with Flexion Therapeutics in 2021.
A handheld cryoanalgesia wand delivering precise cold to a targeted nerve. New FDA-cleared SmartTip tackles chronic low back pain.
A locally administered gene therapy for moderate-to-severe knee osteoarthritis - one injection, three years of data, in the ASCEND study.
Begins life as 21st Century BioPharmaceuticals, built on drug-delivery science.
Lists on the Nasdaq under the ticker PCRX.
Commercial debut of the long-acting local anesthetic that defines the company.
A ~$630M deal adds the ZILRETTA knee-osteoarthritis franchise.
Acquires a high-capacity adenovirus gene-therapy platform; sets new five-year objectives.
Reports $726.4M in FY2025 revenue and the best gross margins in company history.
"We continued to make important progress advancing our 5x30 growth strategy to accelerate topline growth and fuel our transition into an innovative biopharmaceutical organization."
Pacira sells to hospitals, ambulatory surgical centers, and the surgeons and anesthesiologists inside them. If you have had a knee replaced, a hernia repaired, or a shoulder put back together in the United States, there's a real chance your pain plan involved one of its products - and a real chance you never noticed, because the whole point is an uneventful recovery. The company also licenses internationally (an LG Chem deal opens select Asia-Pacific markets) and has EXPAREL working through European regulatory validation.
For clinicians, the pitch is practical: opioid-sparing protocols, reimbursement support, and a health-systems alliance that makes adoption less of a paperwork ordeal. For patients, it's simpler - relief without the side effects and dependency risk that made opioids a public-health crisis in the first place.
The competitive backdrop is not empty. Generic local anesthetics are cheap and familiar. Heron Therapeutics fields its own long-acting analgesic. And in 2025 the category got a jolt from Vertex Pharmaceuticals, whose non-opioid pain drug arrived with considerable noise. Pacira's answer is not to out-shout anyone but to lean on the thing it has spent twenty years accumulating: a delivery platform, a manufacturing footprint, and relationships in the surgical suite that take years to build and longer to displace.
That patience also shapes how Pacira spends. Rather than chase every adjacent idea, it has made concentrated bets - the roughly $630 million Flexion acquisition in 2021 that bought the ZILRETTA knee franchise, and the 2025 purchase of Germany's GQ Bio for a high-capacity adenovirus gene-therapy platform. The latter is the tell. A company comfortable selling liposomes and a cold wand is now reaching toward gene therapy, betting that the future of pain relief might be a single local injection that quiets a joint for years. PCRX-201, its Phase 2 candidate for knee osteoarthritis, is the first expression of that wager.
Return to that operating room. The surgeon is gone, the patient is stirring, and the pain is being managed - not by a pill that risks turning a recovery into a dependency, but by a slow-release suspension or a frozen nerve. Multiply that single room by 2.5 million patients in a year and you have the quiet thing Pacira has actually built: not a blockbuster headline, but a different default. The reach toward the opioid bottle happens a little less often now. That, more than any revenue line, is the change the company set out to make - and it is still making it, one closed wound at a time.
FIG. 2 - Pacira BioSciences, Inc. · Tampa, Florida · Nasdaq: PCRX · "Transforming how the world treats pain."